Scott Lish Sells 25,000 Shares of Alphatec (NASDAQ:ATEC) Stock

by · The Cerbat Gem

Alphatec Holdings, Inc. (NASDAQ:ATEC – Get Free Report) COO Scott Lish sold 25,000 shares of the stock in a transaction that occurred on Thursday, November 20th. The shares were sold at an average price of $19.80, for a total transaction of $495,000.00. Following the completion of the transaction, the chief operating officer owned 672,207 shares of the company’s stock, valued at $13,309,698.60. This trade represents a 3.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Alphatec Price Performance

NASDAQ:ATEC traded up $0.70 during midday trading on Friday, hitting $20.31. 2,306,833 shares of the stock were exchanged, compared to its average volume of 2,126,413. Alphatec Holdings, Inc. has a one year low of $8.69 and a one year high of $21.16. The company has a market capitalization of $3.02 billion, a price-to-earnings ratio of -17.97 and a beta of 1.17. The business has a 50-day moving average price of $16.48 and a two-hundred day moving average price of $14.17. The company has a current ratio of 2.88, a quick ratio of 1.77 and a debt-to-equity ratio of 23.22.

Alphatec (NASDAQ:ATEC – Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The medical technology company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.09. The firm had revenue of $196.50 million for the quarter, compared to the consensus estimate of $182.78 million. During the same period in the previous year, the business posted ($0.28) earnings per share. The business’s revenue for the quarter was up 30.4% compared to the same quarter last year. Alphatec has set its FY 2025 guidance at EPS. Sell-side analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ATEC shares. Needham & Company LLC lifted their target price on Alphatec from $16.00 to $22.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Alphatec in a research note on Monday. Morgan Stanley boosted their target price on shares of Alphatec from $16.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Stifel Nicolaus assumed coverage on shares of Alphatec in a report on Tuesday, October 28th. They set a “buy” rating and a $20.00 target price for the company. Finally, Barclays lifted their price target on shares of Alphatec from $22.00 to $23.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $22.00.

Get Our Latest Stock Report on ATEC

Institutional Investors Weigh In On Alphatec

Large investors have recently made changes to their positions in the company. Aster Capital Management DIFC Ltd purchased a new stake in shares of Alphatec in the 3rd quarter valued at approximately $34,000. Osterweis Capital Management Inc. purchased a new position in Alphatec during the 2nd quarter worth approximately $37,000. Nisa Investment Advisors LLC raised its stake in Alphatec by 22.4% during the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company’s stock valued at $63,000 after purchasing an additional 1,045 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Alphatec in the third quarter valued at $73,000. Finally, FORA Capital LLC purchased a new stake in shares of Alphatec in the first quarter valued at $102,000. Institutional investors and hedge funds own 66.35% of the company’s stock.

About Alphatec

(Get Free Report)

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.

Featured Stories